Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18248512 | 1.00 | FDPS (0.44) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL18248561 | 1.00 | FDPS (0.44) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL4806565 | 1.00 | FDPS (0.44) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL27857502 | 1.00 | FDPS (0.44) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL31290860 | 0.98 | FDPS (0.42) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL18641723 | 0.96 | FDPS (0.47) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL20510878 | 0.96 | FDPS (0.47) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL20954037 | 0.96 | FDPS (0.47) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL10896548 | 0.96 | FDPS (0.47) | FDPSSMPD1CES2SCN5ASCN9A | |
| SCHEMBL29180319 | 0.96 | FDPS (0.47) | FDPSSMPD1CES2SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584241-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054843-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2024-03-14 | — | — | WO | disclosed |